PMID- 36170945
OWN - NLM
STAT- MEDLINE
DCOM- 20230127
LR  - 20230322
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
VI  - 49
IP  - 1
DP  - 2023 Jan
TI  - Effects of H1-Antihistamines on hepatocellular carcinoma risk in patients with 
      type 2 diabetes mellitus.
PG  - 101393
LID - S1262-3636(22)00075-1 [pii]
LID - 10.1016/j.diabet.2022.101393 [doi]
AB  - PURPOSE: H1-antihistamines (AHs) may exert protective effects against cancer. We 
      investigated the association of AH use with hepatocellular carcinoma (HCC) risk 
      in type 2 diabetes mellitus (T2DM) patients without hepatitis B virus (HBV) or 
      hepatitis C virus (HCV) infection. METHODS: The data of patients with T2DM 
      enrolled from Taiwan's National Health Insurance Research Database were examined 
      for the period of January 1, 2008, to December 31, 2018. We used the Kaplan-Meier 
      method and Cox proportional hazards regression to evaluate the AH use-HCC risk 
      association. RESULTS: After 1:1 propensity score matching was performed, the two 
      cohorts were each divided into AH users (n = 47,990) and nonusers (n = 47,990). 
      The risk of HCC was significantly lower in AH users than in AH nonusers (adjusted 
      hazard ratio [aHR]: 0.55 95% confidence interval [95% CI], 0.46 to 0.67; IRR: 
      0.70; 95% CI, 0.60 to 0.84), respectively. The dose-response relationship between 
      AH use and HCC risk was also observed (aHRs: 0.58, 0.56, 0.50, and 0.41 for 
      28-35, 36-49, 50-77, and >77 cumulative defined daily doses of AH, respectively). 
      CONCLUSION: AH use can reduce HCC risk in T2DM patients without HBV or HCV 
      infection in a dose-dependent manner.
CI  - Copyright (c) 2022 Elsevier Masson SAS. All rights reserved.
FAU - Wu, Szu-Yuan
AU  - Wu SY
AD  - 1Graduate Institute of Business Administration, College of Management, Fu Jen 
      Catholic University, New Taipei City, Taiwan; Artificial Intelligence Development 
      Center, Fu Jen Catholic University, New Taipei City, Taiwan; Department of Food 
      Nutrition and Health Biotechnology, College of Medical and Health Science, Asia 
      University, Taichung, Taiwan; Big Data Center, Lo-Hsu Medical Foundation, Lotung 
      Poh-Ai Hospital, Yilan, Taiwan; Division of Radiation Oncology, Lo-Hsu Medical 
      Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan; Department of Healthcare 
      Administration, College of Medical and Health Science, Asia University, Taichung, 
      Taiwan; Centers for Regional Anesthesia and Pain Medicine, Taipei Municipal Wan 
      Fang Hospital, Taipei Medical University, Taipei, Taiwan.
FAU - Chen, Wan-Ming
AU  - Chen WM
AD  - 1Graduate Institute of Business Administration, College of Management, Fu Jen 
      Catholic University, New Taipei City, Taiwan; Artificial Intelligence Development 
      Center, Fu Jen Catholic University, New Taipei City, Taiwan.
FAU - Chen, Yi-Chan
AU  - Chen YC
AD  - Department of General Surgery, Chang Gung Memorial Hospital, Keelung, Taiwan.
FAU - Chiang, Ming-Feng
AU  - Chiang MF
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan 265, Taiwan.
FAU - Lee, Ming-Che
AU  - Lee MC
AD  - Department of Surgery, Taipei Municipal Wanfang Hospital, Taipei, Taiwan; College 
      of Medicine, Taipei Medical University, Taipei, Taiwan.
FAU - Soong, Ruey-Shyang
AU  - Soong RS
AD  - Department of Surgery, Taipei Municipal Wanfang Hospital, Taipei, Taiwan; College 
      of Medicine, Taipei Medical University, Taipei, Taiwan. Electronic address: 
      kodlp62@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20220925
PL  - France
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
RN  - 0 (Histamine Antagonists)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/epidemiology
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology
MH  - *Liver Neoplasms/epidemiology
MH  - *Hepatitis C/complications/drug therapy/epidemiology
MH  - Histamine Antagonists
OTO - NOTNLM
OT  - H1-Antihistamines
OT  - Hepatocellular Carcinoma
OT  - Type 2 Diabetes Mellitus
OT  - dose-dependent
OT  - incidence rate ratio
COIS- Declaration of Competing Interest The authors have no potential conflicts of 
      interest to declare. The datasets supporting the study conclusions are included 
      within the manuscript.
EDAT- 2022/09/29 06:00
MHDA- 2023/01/28 06:00
CRDT- 2022/09/28 19:24
PHST- 2022/07/19 00:00 [received]
PHST- 2022/09/18 00:00 [revised]
PHST- 2022/09/19 00:00 [accepted]
PHST- 2022/09/29 06:00 [pubmed]
PHST- 2023/01/28 06:00 [medline]
PHST- 2022/09/28 19:24 [entrez]
AID - S1262-3636(22)00075-1 [pii]
AID - 10.1016/j.diabet.2022.101393 [doi]
PST - ppublish
SO  - Diabetes Metab. 2023 Jan;49(1):101393. doi: 10.1016/j.diabet.2022.101393. Epub 
      2022 Sep 25.